A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
Recruiting · NCT06526923 · Registry updated 2024-11-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Aspiration, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Recruiting | Phase 1 / Phase 2 | 2024-11-25 | NCT06526923 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Spirovant Sciences, Inc. | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Children's Hospital, Brigham & Women's Hospital | Boston | United States | 3 |
| Columbia University | New York | United States | 154 |
| Hospital at University of Pennsylvania | Philadelphia | United States | 1 |
| University of Kansas Medical Center | Kansas City | United States | 240 |